Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/Cisplatin vs Cisplatin/5-FU in Neoadjuvant Chemoradiation for ESCC
NCT03623737Phase 3Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Mar 2017
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: pathological complete response at 2 years. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03623737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623737.